Lantern Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lantern Pharma (LTRN).

Price Target Range — 1 Quarters

Analyst Consensus — 2 Analysts

1Buy

1Hold

Consensus RatingBuy# Analysts2Avg. Consensus PT$25Upside to Avg. PT+3840.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 2, 2025	Lake Street	Chad Messer	Initiate	Buy	$25
Apr 25, 2024	HC Wainwright & Co.	Emily Bodnar	Maintained	Neutral	—

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25

Lake Street analyst Chad Messer initiates coverage on Lantern Pharma (NASDAQ:LTRN) with a Buy rating and announces Price Target of $25.

Benzinga Newsdesk

PRO
Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation

https://scr.zacks.com/files/News/2024/Zacks_SCR_Research_08122024_LTRN_Vandermosten.pdf

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Lantern Pharma

HC Wainwright & Co. analyst Emily Bodnar reiterates Lantern Pharma (NASDAQ:LTRN) with a Neutral.

Benzinga Newsdesk

Watching Lantern Pharma; Zacks Small-Cap Research Sets $26 Price Valuation

https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_08102023_LTRN_Vandermosten.pdf

Happy Mohamed

PRO
EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

EF Hutton analyst Michael King reiterates Lantern Pharma (NASDAQ:LTRN) with a Buy and maintains $11 price target.

Benzinga Newsdesk

PRO
EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

EF Hutton analyst Michael King maintains Lantern Pharma (NASDAQ:LTRN) with a Buy and maintains $11 price target.

Benzinga Newsdesk

Lantern Pharma Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Lantern Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Lake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25

PRO
Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation

PRO
HC Wainwright & Co. Reiterates Neutral on Lantern Pharma

Watching Lantern Pharma; Zacks Small-Cap Research Sets $26 Price Valuation

PRO
EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

PRO
EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

People Also Watch

People Also Watch

Lantern Pharma Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Lantern Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25

PROWatching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation

PROHC Wainwright & Co. Reiterates Neutral on Lantern Pharma

Watching Lantern Pharma; Zacks Small-Cap Research Sets $26 Price Valuation

PROEF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

PROEF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target

People Also Watch

People Also Watch

PRO
Lake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25

PRO
Watching Lantern Pharma; Zacks Small Cap Research Gives Stock $26 Price Valuation

PRO
HC Wainwright & Co. Reiterates Neutral on Lantern Pharma

PRO
EF Hutton Reiterates Buy on Lantern Pharma, Maintains $11 Price Target

PRO
EF Hutton Maintains Buy on Lantern Pharma, Maintains $11 Price Target